Compare · BSX vs SINT
BSX vs SINT
Side-by-side comparison of Boston Scientific Corporation (BSX) and SiNtx Technologies Inc. (SINT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SINT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 4781.7x SINT ($13.4M).
- BSX has been more active in the news (5 items in the past 4 weeks vs 3 for SINT).
- BSX has more recent analyst coverage (25 ratings vs 1 for SINT).
- Company
- Boston Scientific Corporation
- SiNtx Technologies Inc.
- Price
- $44.38+0.50%
- $1.75-6.42%
- Market cap
- $63.97B
- $13.4M
- 1M return
- -
- +4.79%
- 1Y return
- -
- -56.03%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 1
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
SiNtx Technologies Inc.
Sintx Technologies, Inc., an advanced materials company, researches, develops, manufactures, and commercializes silicon nitride ceramics in the United States, Europe, and South America. It offers ceramic based solutions for various medical, industrial, and antipathogenic applications. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products. It has a collaboration agreement with Oxford Performance Materials, Inc. to develop a poly-ether-ketone-ketone silicon nitride composite based on OXPEKK SC solution casting technology. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest SINT
- SEC Form 8-K filed by SiNtx Technologies Inc.
- SiNtx Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance
- SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts
- SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- SEC Form EFFECT filed by SiNtx Technologies Inc.
- SiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement
- SiNtx Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by SiNtx Technologies Inc.